- Home
- BCDA vs DOMH Comparison
BCDA vs DOMH Comparison
Compare BCDA & DOMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- DOMH
- Stock Information
- Founded
- BCDA N/A
- DOMH 1967
- Country
- BCDA United States
- DOMH United States
- Employees
- BCDA N/A
- DOMH N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- DOMH Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- DOMH Health Care
- Exchange
- BCDA Nasdaq
- DOMH Nasdaq
- Market Cap
- BCDA 7.9M
- DOMH 7.3M
- IPO Year
- BCDA N/A
- DOMH N/A
- Fundamental
- Price
- BCDA $2.18
- DOMH $1.23
- Analyst Decision
- BCDA Strong Buy
- DOMH
- Analyst Count
- BCDA 1
- DOMH 0
- Target Price
- BCDA $25.00
- DOMH N/A
- AVG Volume (30 Days)
- BCDA 52.4K
- DOMH 68.6K
- Earning Date
- BCDA 11-13-2024
- DOMH 11-08-2024
- Dividend Yield
- BCDA N/A
- DOMH N/A
- EPS Growth
- BCDA N/A
- DOMH N/A
- EPS
- BCDA N/A
- DOMH N/A
- Revenue
- BCDA $71,000.00
- DOMH $12,589,000.00
- Revenue This Year
- BCDA N/A
- DOMH N/A
- Revenue Next Year
- BCDA N/A
- DOMH N/A
- P/E Ratio
- BCDA N/A
- DOMH N/A
- Revenue Growth
- BCDA N/A
- DOMH 1117.50
- 52 Week Low
- BCDA $1.63
- DOMH $0.83
- 52 Week High
- BCDA $8.85
- DOMH $3.20
- Technical
- Relative Strength Index (RSI)
- BCDA 49.10
- DOMH 49.20
- Support Level
- BCDA $2.05
- DOMH $1.00
- Resistance Level
- BCDA $2.36
- DOMH $1.29
- Average True Range (ATR)
- BCDA 0.21
- DOMH 0.14
- MACD
- BCDA -0.00
- DOMH 0.02
- Stochastic Oscillator
- BCDA 46.43
- DOMH 86.96
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.